StockWatch
·

RIR Power Electronics Ltd Q2 FY27 Results

RIRQ2 FY27 Results
Filing
Result:Weak· Market: Down#Margin squeeze#Base effect

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue33.9825.1%32.5%
Total Income35.5927.4%35.3%
Expenditure30.0526.4%36.9%
PBT5.5433.4%27.2%
Net Profit4.4541.7%41.2%
OPM13.62%1.04pp3.39pp
NPM12.50%1.27pp0.53pp
EPS0.5643.6%19.1%
View full financials

Industrials core metric (EBITDA margin) fell for a third straight quarter to 13.62% from 17.01% YoY, missing management's own 15-17% guidance, with flat net margin propped up only by a one-off doubling of other income and a lower tax rate rather than core operating performance.

RIR POWER ELECTRONICS LTD · QQ2 FY-2027 · THE CALL

Core growth solid, epitaxy launch delayed by govt approval

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

03 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Q2 beat ₹30+ Cr target; epitaxy launch guidance (Nov–Dec) at risk pending govt clearance

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

RIR beat Q2 guidance at ₹34 Cr with 32.5% YoY growth and healthy ₹39 Cr order backlog, validating core business momentum. However, the critical catalyst—SiC epitaxy launch—faces government regulatory delays that could slip into Q4, and commercialization success is unproven. Margin compressed 40 bps YoY to 16.6% due to raw-material cost inflation. Near-term hinges on epitaxy execution; long-term opportunity is real but timing is uncertain.

₹34 Cr

Revenue · +32.5% YoY

₹4.4 Cr

Reported PAT · +41.2% YoY

Compressing

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Q2 revenue ₹34 Cr is sustainable recurring base

OVERSTATED

Q1 ₹27.2 Cr, Q2 ₹34 Cr shows growth but order book ₹39 Cr limits runway without epitaxy

32.5% YoY revenue growth vs Q2 FY26

MET

₹33.98 Cr vs ₹25.64 Cr = 32.5% YoY confirmed

No one-time items, all routine operating revenue

MET

Management stated: These are constantly operating routine revenue, no one-time events

Epitaxy facility to launch Q3 (Nov-Dec) 2026

MISS

Almost done, but waiting govt clearances; management hoping Nov, definitely Dec - timeline at risk

Order backlog improved significantly

MET

Now ₹39 Cr, was ₹17.4 Cr Mar 31 (2.24x improvement); strong but over-concentration risk

Earnings quality

What changed since the last call

Deltas vs. the prior call

Order backlog surge

Upgrade

₹39 Cr vs ₹17.4 Cr on Mar 31 (2.24x); backlog ~115% of quarterly revenue, validates demand

Epitaxy timeline uncertainty

Downgrade

Govt clearances delayed; Nov–Dec launch now hoped for, not confirmed (prior: Q3 FY'27 expected)

Margin pressure sustained

Downgrade

EBITDA margin 16.6% vs 17% prior year; geopolitical raw-material inflation ongoing

The Q&A

Analysts pressed hard on epitaxy timeline (3 questions), forward guidance (dodged repeatedly), capacity specifics, and ₹100M revenue aspirations. Management held firm on not giving FLS but defended backlog and market position; tone was defensive on govt delays (Mehta: frustrated with clearance pace).

The exchanges that mattered

Epitaxy plant timeline — Charchit Maloo, Gemini Capital

Dodged

Almost everything done, waiting govt of Odisha clearances (building, fire clearance in process). No firm timeline; depends on govt approvals.

Forward revenue and EBITDA — Charchit Maloo, Gemini Capital

Dodged

We don't give forward-looking statements. First and second quarter growth shows we're not looking to go back; confident on growth trajectory.

Base-case revenue run-rate — Prateek Giri, Shubh Labh Research

Answered

Almost close to ₹30 Cr. Order backlog ₹39 Cr. Shifted problem from market to plant. Working on productivity to grow base. Yes, ₹34 Cr should be base case.

Epitaxy reactor capacity — Keshav, Niveshaay

Partial

Expecting ₹12–15 Cr revenue next 4–6 months from epitaxy. Output depends on wafer specs, thickness, coating microns. ~5000 wafers/month possible; productivity varies by spec.

Capacity utilization and backlog — Saurabh Jain, Sequent Investment

Answered

LPD at ~90% utilization. Equipment no capacity issue, mostly assembly. Order backlog ₹39 Cr as of Q2 end.

FY27–28 revenue guidance — Saurabh Jain, Sequent Investment

Dodged

We don't give forward-looking statements.

BSV HVDC strategic opportunity — Vijendra, Individual investor

Answered

Already participating, submitted interest. Ministry & power ministry looking at development plan. Will submit plan in ~1 month.

SiC factory utilization timeline — Vijendra, Individual investor

Partial

Set to go for production. Hoping November, definitely December production start. Govt clearances coming through. No detailed utilization forecast given.

Competitive position and scale — Somnath Paul, Relay Investments

Answered

Unique position as highest value-chain player in India (SiC to systems). Others start from scratch; RIR has 2.5-year head start. Focus on high-value, low-competitive products. Railway/defense/HVDC offer infrastructure tailwinds. SiC epi will be key product differentiator.

Revenue scale aspirations — Somnath Paul, Relay Investments

Dodged

Management vague: aspirations are per the tenders available. Order book will be main driver once Odisha project launches. Ramesh: once Odisha phase completes, numbers will be totally different.

FY29 inflection and growth drivers — Ashish Soni, MM Capital

Answered

Growth from all verticals; not leaving anything. Railway 70–80% growth potential. Defense in early stages. Focused on high-value, high-margin products. Will avoid blanket forward guidance but optimistic on future.

Guidance

Forward guidance and management's confidence

Q2/3/4 quarterly core business ₹30+ Cr (vs Q1 ₹27.2 Cr)

High

Q2 delivered ₹34 Cr, beating target; ₹39 Cr backlog supports near-term runway

SiC epitaxy ₹12–15 Cr H2 FY'27 (9-month period)

Medium

Depends on Nov–Dec plant launch and govt clearances; reaffirmed on call

Sustainable EBITDA margin 15–17% (from Q1 call)

Medium

Q2 at 16.6%; raw-material inflation ongoing but within band so far

Epi-wafer margin 20–25% (long-term unproven)

Low

Not validated; epitaxy is new product, margins dependent on mix and scale

FY'27 capex ₹100–120 Cr for Odisha Phase 1

Medium

Phase 1B (packaging) still awaiting bank approval; Phase 1A (epitaxy) in final approval stage

Risks the call surfaced

Ranked by how much they should concern a holder

Epitaxy regulatory delay

High

Odisha facility awaiting govt building and fire clearances; no firm launch date. Slippage could push production start to Q4 or later, delaying ₹12–15 Cr H2 revenue by 6+ months and forcing guidance miss.

SiC product commercialization

High

SiC epitaxial wafers are new product with no commercial track record. Reactor recently installed; volume production unproven. Customer acceptance, process yields, and cost competitiveness vs global players unvalidated. Loss of design wins or margin compression could derail ₹12–15 Cr H2 plan.

Government policy / order dependency

Medium

Railway, defense, and HVDC (BSV) orders are key growth drivers but all government-backed or government-specified. Policy changes, procurement delays, or priority shifts could stall order flow. Railway business is repeat but subject to ministry capex cycles.

Margin compression from raw-material inflation

Medium

EBITDA margin fell 40 bps YoY to 16.6% due to 2.8% raw-material cost inflation (geopolitical). If inflation persists or accelerates, margin could fall below 15% target band, pressuring profits even if revenue grows.

Order backlog burn-out without epitaxy

Medium

Current backlog ₹39 Cr is only ~115% of quarterly revenue. At ₹34 Cr/quarter run-rate, backlog depletes in ~4–5 quarters without new orders. Core business (LPD, HPD, Equipment) has limited growth headroom; new orders depend on railway/defense/HVDC tenders. If epitaxy launch slips and new orders don't materialize, Q4–Q1 FY'28 could see revenue stall or decline.

Large capex burden on balance sheet

Medium

FY'27 capex target ₹100–120 Cr is very large vs quarterly profit of ₹4.4 Cr (~6 quarters of profit). Phase 1B (packaging) awaiting bank loan approval. If funding is delayed, equity dilution or debt/leverage could increase. Loss of government subsidy (₹5% interest subsidy) would worsen economics.

Management

Score 6/10. Decent clarity on operations and product roadmap; evasive on forward guidance (repeatedly declined to give FY27–28 targets despite analyst pressure). Transparent on backlog and order book. Q2 beat Q1 guidance (₹34 Cr vs ₹30+ Cr target); epitaxy delay is first significant miss on timeline. Operating leverage intact; margins held within band despite inflation.

What to watch next
  • 1 · Q3 FY27 (Nov–Dec)

    Epitaxy plant launch pending Odisha govt regulatory clearances; critical for H2 ₹12–15 Cr target

  • 2 · Q3–Q4 FY27

    Railway repeat orders and first defense trial orders expected; 70–80% growth potential

  • 3 · H2 FY27

    SiC epitaxy product validation with international and domestic customers; de-risks long-term TAM

Near-term hinges on epitaxy execution; long-term opportunity is real but timing is uncertain.

Informational and educational content only. Not investment advice.